Table 6. Trials of bevacizumab integrated into chemoradiation schedules.
| Trial | Patient numbers | Regimen | Pathologic complete response rate |
|---|---|---|---|
| Czito 2007 (64) | 11 | Bev, Cape, Ox, 50.4 Gy | 18% (2/11) |
| Willet 2010 (65) | 32 | Bev, CI 5-FU, 50.4 Gy | 16% (5/32) |
| Crane 2010 (66) | 25 | Bev, Cape, 50.4 Gy | 32% (8/25) |
| Koukourakis 2010 (67) | 19 | Bev, Cape, Amifos 34 Gy/10# | 37% (7/19) |
| Martinez Villacampa 2011 (68) | 39 | Bev, Cape, 45 Gy | 8% (3/39) |
| Liang 2011 (69) | 28 | Bev, 5-FU, Leuc, Ox, 45 Gy | 25% (7/28) |
| Nogue 2011 (70) | 47 | Bev, Cape, Ox induction X4 | 34% (16/47) |
| Velenik 2011 (71) | 61 | Bev, Cape, 50.4 Gy/28# | 13% (8/61) |
| diPetrillo 2012 (72) | 26 | Bev, FOLFOX induction | 19% (5/26) |
| Bev, 5FU(PVI), Ox, 50.4 Gy/28# | |||
| Gasparini 2012 (73) | 43 | Bev, Cape, 50.4 G/28# | 14% ( 6/43) |
| Resch 2012 (74) | 8 | Bev, Cape, 50.4 G/28# | 25% (2/8) |
| Kennecke 2012 (75) | 42 | Bev, Cape, Ox, 50.4 Gy/28# | 17% (7/42) |
| Spigel 2012 (76) | 35 | Bev, CI 5-FU, 50.4 Gy | 27% (9/35) |
| Landry 2013 (77) | 54 | Bev, Cape, Ox, 50.4 G/28# | 17% (9/54) |
| Dellas 2013 (78) | 70 | Bev, Cape, Ox, 50.4 G/28# | 17% (12/70) |
| Total | 540 | 106/540 (19.6%) |
Bev, bevacizumab; 5-FU, 5-Fluorouracil; Cape, capecitabine; Ox, oxaliplatinÂ